Clinical trial / 2018
Daily bioavailable curcumin for 18 months improved memory and attention and reduced amygdala FDDNP binding in non-demented adults.
Forty non-demented adults aged 51-84 were randomized to receive 90 mg curcumin twice daily as Theracurmin (N=21) or placebo (N=19) for 18 months. Curcumin improved verbal memory (SRT Consistent Long-Term Retrieval: ES=0.63, p=0.002; between-group ES=0.68, p=0.05), visual memory (BVMT-R Recall: ES=0.50, p=0.01; BVMT-R Delay: ES=0.51, p=0.006), and attention (ES=0.96, p<0.0001; between-group ES=0.67, p=0.04). FDDNP-PET binding decreased in the amygdala with curcumin (ES=-0.41, p=0.04; between-group ES=0.48, p=0.07) and remained unchanged in the hypothalamus with curcumin while increasing with placebo (between-group ES=0.55, p=0.02).
- Study type
- Double-blind, placebo-controlled randomized trial
- Who was studied
- 40 non-demented adults aged 51-84 years
- What was measured
- Verbal and visual memory, attention, and brain amyloid/tau accumulation (FDDNP-PET)
THE PAPER
Memory and Brain Amyloid and Tau Effects of a Bioavailable Form of Curcumin in Non-Demented Adults: A Double-Blind, Placebo-Controlled 18-Month Trial.
Small GW, Siddarth P, Li Z, Miller KJ, Ercoli L, Emerson ND, Martinez J, Wong KP, Liu J, Merrill DA, Chen ST, Henning SM, Satyamurthy N, Huang SC, Heber D, Barrio JR. Am J Geriatr Psychiatry, 2018.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.